Posted on April 23, 2014
After a day-long hearing, yesterday an FDA advisory panel rejected Moxduo, the combination oxycodone and morphine pill. All 14 specialists voted against it.
Moxduo combined smaller amounts of oxycodone and morphine into one pill, to more quickly relieve severe pain and with fewer side effects. In the end, however, FDA advisers saw no “advantages over regular oxycodone and morphine.” Those favoring the rejection also cited the possible abuse of the combo pill.
To read the article, click here.
Read more about the drug here.
To read the committee briefing document, click here.